Indaptus Therapeutics Inc. (NASDAQ: INDP)
$2.18
-0.0191 ( -0.87% ) 10.7K
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
Market Data
Open
$2.18
Previous close
$2.20
Volume
10.7K
Market cap
$18.19M
Day range
$2.15 - $2.21
52 week range
$1.56 - $4.08
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 14 | Jun 07, 2024 |
4 | Insider transactions | 1 | Jun 07, 2024 |
4 | Insider transactions | 1 | Jun 07, 2024 |
4 | Insider transactions | 1 | Jun 07, 2024 |
4 | Insider transactions | 1 | Jun 07, 2024 |
4 | Insider transactions | 1 | Jun 07, 2024 |
4 | Insider transactions | 1 | Jun 07, 2024 |
8-k | 8K-related | 13 | May 22, 2024 |
10-q | Quarterly Reports | 53 | May 08, 2024 |
8-k | 8K-related | 15 | May 08, 2024 |